On Nov 27, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $182 to $217.
Morgan Stanley analyst Matthew Harrison maintains with a buy rating, and maintains the target price at $200.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and maintains the target price at $200.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and adjusts the target price from $210 to $217.
BMO Capital analyst Kostas Biliouris maintains with a buy rating, and maintains the target price at $200.
Mizuho Securities analyst Uy Ear maintains with a buy rating, and sets the target price at $200.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following the announcement of an agreement with Arrowhead concerning licenses for four clinical and three preclinical programs, analysts maintain a positive outlook on the Elevidys launch. This deal, backed by substantial financial commitments, is seen as an enhancement to the pipeline. It potentially broadens revenue streams beyond existing offerings, addressing investor demands for greater diversification opposed to reliance on singular gene therapies.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
